Genmab — August 2013
-
“Janssen thinks [dara] will be very big – they describe it as potentially the new backbone treatment for multiple myeloma in all lines of therapy,” Mr van de Winkel says.
-
Mr van de Winkel describes dara as “the most potent naked antibody I have seen in my 25 years of antibody development”,
-
stærk kommunikation
-
den rykker pænt op idag. måske er momentum ved at indfinde sig
-
det er en voldsom valuering. har selv været ONXX aktionær tidligere
-
ONXX er mere udviklet end genmab, men slet ikke i niveau der retfærdiggør den prisforskel
-
Har Onyx andet end Carfilzomib med blockbuster-potentiale?
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind